Effect of long-term treatment with low-dose mifepristone on the endometrium

David T. Baird, D. T. Baird, A Brown, Amy Brown, Hilary Critchley, H O D Critchley, Alistair Williams, A R Williams, S Lin, Si-Qi Lin, L Cheng, Lei Cheng
Human Reproduction · 2003 · vol. 18(1) , pp. 61–68 · doi:10.1093/humrep/deg022 · PMID:12525442 · W2133700168
Non-randomised trial OA: closed CC0 ⤵ 33 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

Low-dose mifepristone (2-5 mg daily) suppressed ovulation and menstruation in most women, leading to inactive proliferative or cystic endometrial changes without hyperplasia or atypia.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Mifepristone in low daily doses has contraceptive potential by inhibiting ovulation and menstruation. Because follicular development is maintained, the endometrium is exposed to estrogen for prolonged periods unopposed by progesterone. METHODS: Endometrial biopsies were collected from 90 women in Edinburgh and Shanghai before (late proliferative) and 60 and 120 days after taking 2 or 5 mg mifepristone per day for 120 days. RESULTS: Ovulation and menstruation were inhibited in >90% of cycles and estrogen production was similar to that observed during the follicular phase of the control cycle. By 120 days, endometrial thickness increased significantly in women in Edinburgh but decreased in Shanghai. Endometrial histology showed inactive proliferative or cystic changes with dense stroma. There was a significant decrease in markers of proliferation, i.e. mitotic index and Ki67 staining. There were no pregnancies in a total of 200 women-months in 50 sexually active women who used no other method of contraception. CONCLUSIONS: We confirm that ovulation and menstruation were suppressed in the majority of cycles and there was asynchrony between ovarian activity and endometrial histology, which showed no signs of hyperplasia or atypia. These preliminary data suggest that daily low-dose mifepristone is potentially a safe estrogen-free contraceptive pill which has the added health benefit of amenorrhoea.

My notes (saved in your browser only)

MeSH descriptors

Contraceptives, Oral, Synthetic Endometrium Mifepristone Adult Cell Division Cell Division Contraceptives, Oral, Synthetic Dose-Response Relationship, Drug Drug Administration Schedule Endometrium Endometrium Endometrium Female Humans Menstruation Menstruation Mifepristone Mitotic Index Ovary Ovary

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (33)

Cited by (31)

Source provenance

openalex
last seen: 2026-05-11T06:41:50.100108+00:00
pubmed
last seen: 2026-10-08T21:00:51.939714+00:00
License: CC0 · commercial use OK